Quince Therapeutics, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
On May 18, 2026, Quince Therapeutics acquired Orphai Therapeutics via merger, issuing 67,101 shares of Series C Preferred Stock (convertible to 3.5M common shares) to Orphai stockholders. Concurrently, Quince closed a $115M PIPE on May 21, 2026, selling 144,201 shares of Series C Preferred Stock at $797.50/share and warrants to purchase 72,100 shares at $996.90/share to new and returning investors, generating up to $187M total (including warrant exercise proceeds). Post-conversion, common shares outstanding increase from 1.0M to 12.0M.
Why this rating
Acquisition + $115M cash raise is ~1.8x company market cap, substantially expanding capital for operations and reducing dilution pressure; material for $64M company.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.